Diversified Trust’s Sage Therapeutics SAGE Stock Holding History

Diversified Trust’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,049	Closed	-$215K	–	872
2021 Q4	$215K	Buy	+5,049	New	+$211K	0.01%	750

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Diversified Trust's SAGE Position: Q1 2022 in Review

Diversified Trust sold out of Sage Therapeutics (SAGE) in Q1 2022, closing a stake of 5,049 shares — an estimated $215K sold.

Diversified Trust first reported a position in SAGE in Q4 2021 and held it in 1 quarter. The position peaked at $215K in Q4 2021. 211 funds tracked by Wall St. Rank hold SAGE as of Q1 2022.

Diversified Trust reported no remaining Sage Therapeutics position as of Q1 2022 after selling out during the quarter.
Diversified Trust sold 5,049 Sage Therapeutics shares in Q1 2022, an estimated $215K.
Diversified Trust first reported a position in Sage Therapeutics in Q4 2021 and held it in 1 quarter.
Diversified Trust's Sage Therapeutics position peaked at $215K in Q4 2021.
211 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2022.

Based on Diversified Trust's 13F filing for Q1 2022, filed 7 Apr 2022.